BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 23938289)

  • 1. Prognostic factors in patients with advanced cancer: a comparison of clinicopathological factors and the development of an inflammation-based prognostic system.
    Laird BJ; Kaasa S; McMillan DC; Fallon MT; Hjermstad MJ; Fayers P; Klepstad P
    Clin Cancer Res; 2013 Oct; 19(19):5456-64. PubMed ID: 23938289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of systemic inflammation-based markers in advanced pancreatic cancer.
    Martin HL; Ohara K; Kiberu A; Van Hagen T; Davidson A; Khattak MA
    Intern Med J; 2014 Jul; 44(7):676-82. PubMed ID: 24750233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of a systemic inflammatory response in patients undergoing multimodality therapy for advanced colorectal cancer.
    Inoue Y; Iwata T; Okugawa Y; Kawamoto A; Hiro J; Toiyama Y; Tanaka K; Uchida K; Mohri Y; Miki C; Kusunoki M
    Oncology; 2013; 84(2):100-7. PubMed ID: 23147449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of inflammation-based prognostic scores in patients with cancer. A Glasgow Inflammation Outcome Study.
    Proctor MJ; Morrison DS; Talwar D; Balmer SM; Fletcher CD; O'Reilly DS; Foulis AK; Horgan PG; McMillan DC
    Eur J Cancer; 2011 Nov; 47(17):2633-41. PubMed ID: 21724383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostication in advanced cancer: a study examining an inflammation-based score.
    Partridge M; Fallon M; Bray C; McMillan D; Brown D; Laird B
    J Pain Symptom Manage; 2012 Aug; 44(2):161-7. PubMed ID: 22732417
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modified Glasgow prognostic score is an independent prognostic factor in patients with cervical cancer undergoing chemoradiotherapy.
    Xiao Y; Ren YK; Cheng HJ; Wang L; Luo SX
    Int J Clin Exp Pathol; 2015; 8(5):5273-81. PubMed ID: 26191228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of the Modified Glasgow Prognostic Score in Advanced Cancer Patients Receiving Palliative Care.
    Pantano Nde P; Paiva BS; Hui D; Paiva CE
    J Pain Symptom Manage; 2016 Feb; 51(2):270-7. PubMed ID: 26598040
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammation and Performance Status: The Cornerstones of Prognosis in Advanced Cancer.
    Rocha BMM; Dolan RD; Paiva CE; McGovern J; Paiva BSR; Preto DD; McMillan DC; Maia YCP; Laird BJ
    J Pain Symptom Manage; 2023 Apr; 65(4):348-357. PubMed ID: 36493981
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The inflammation-based modified Glasgow Prognostic Score in patients with vulvar cancer.
    Hefler-Frischmuth K; Seebacher V; Polterauer S; Tempfer C; Reinthaller A; Hefler L
    Eur J Obstet Gynecol Reprod Biol; 2010 Mar; 149(1):102-5. PubMed ID: 20080329
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognosis in advanced lung cancer--A prospective study examining key clinicopathological factors.
    Simmons CP; Koinis F; Fallon MT; Fearon KC; Bowden J; Solheim TS; Gronberg BH; McMillan DC; Gioulbasanis I; Laird BJ
    Lung Cancer; 2015 Jun; 88(3):304-9. PubMed ID: 25870155
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The glasgow prognostic score as a predictor of survival in patients with potentially resectable pancreatic adenocarcinoma.
    La Torre M; Nigri G; Cavallini M; Mercantini P; Ziparo V; Ramacciato G
    Ann Surg Oncol; 2012 Sep; 19(9):2917-23. PubMed ID: 22488099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical utility of the pretreatment glasgow prognostic score in patients with advanced inoperable non-small cell lung cancer.
    Leung EY; Scott HR; McMillan DC
    J Thorac Oncol; 2012 Apr; 7(4):655-62. PubMed ID: 22425914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of inflammation-based prognostic score on mortality of patients undergoing chemotherapy for far advanced or recurrent unresectable colorectal cancer.
    Ishizuka M; Nagata H; Takagi K; Kubota K
    Ann Surg; 2009 Aug; 250(2):268-72. PubMed ID: 19638907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Glasgow prognostic score as a prognostic factor in metastatic castration-resistant prostate cancer treated with docetaxel-based chemotherapy.
    Linton A; Pond G; Clarke S; Vardy J; Galsky M; Sonpavde G
    Clin Genitourin Cancer; 2013 Dec; 11(4):423-30. PubMed ID: 23816526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of the systemic inflammation-based Glasgow prognostic score: a Glasgow Inflammation Outcome Study.
    Proctor MJ; Horgan PG; Talwar D; Fletcher CD; Morrison DS; McMillan DC
    Cancer; 2013 Jun; 119(12):2325-32. PubMed ID: 23575969
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inflammation-based prognostic score predicts biliary stent patency in patients with unresectable malignant biliary obstruction.
    Iwasaki Y; Ishizuka M; Kato M; Kita J; Shimoda M; Kubota K
    Anticancer Res; 2014 Jul; 34(7):3617-22. PubMed ID: 24982377
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validation of the modified Glasgow Prognostic Score (mGPS) in recurrent ovarian cancer (ROC) - Analysis of patients enrolled in the GCIG Symptom Benefit Study (SBS).
    Roncolato FT; Berton-Rigaud D; O'Connell R; Lanceley A; Sehouli J; Buizen L; Okamoto A; Aotani E; Lorusso D; Donnellan P; Oza A; Avall-Lundqvist E; Berek J; Hilpert F; Ledermann JA; Kaminsky MC; Stockler MR; King MT; Friedlander M
    Gynecol Oncol; 2018 Jan; 148(1):36-41. PubMed ID: 29107348
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic inflammation and survival of patients with prostate cancer: evidence from the Glasgow Inflammation Outcome Study.
    Shafique K; Proctor MJ; McMillan DC; Qureshi K; Leung H; Morrison DS
    Prostate Cancer Prostatic Dis; 2012 Jun; 15(2):195-201. PubMed ID: 22343838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the prognostic value of MUST, ECOG-PS, mGPS and CT derived body composition analysis in patients with advanced lung cancer.
    Abbass T; Dolan RD; MacLeod N; Horgan PG; Laird BJ; McMillan DC
    Clin Nutr ESPEN; 2020 Dec; 40():349-356. PubMed ID: 33183562
    [TBL] [Abstract][Full Text] [Related]  

  • 20. "How Long Have I Got?"-A Prospective Cohort Study Comparing Validated Prognostic Factors for Use in Patients with Advanced Cancer.
    Simmons C; McMillan DC; Tuck S; Graham C; McKeown A; Bennett M; O'Neill C; Wilcock A; Usborne C; Fearon KC; Fallon M; Laird BJ;
    Oncologist; 2019 Sep; 24(9):e960-e967. PubMed ID: 30975922
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.